EUSA already markets two oncology drugs and is seeking to build its presence in the rare disease market with Sylvant, which has been approved in the US since 2014 to treat multicentric Castleman ...
Castleman disease, organomegaly, edema, endocrinopathy, skin changes, papilledema). In this study the medical records of 170 patients diagnosed with POEMS syndrome were analyzed retrospectively.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback